Clinical trials: Glioblastoma Multiforme
Glioblastoma Multiforme, Glioblastoma
Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme
The purpose of this research study is to determine if an investigational dendritic cell vaccine, called pp65 DC, is effective for the treatment of a specific type of brain tumor called glioblastoma (GBM) when given with stronger…
- Conditions
- Glioblastoma Multiforme, Glioblastoma, Malignant Glioma, Astrocytoma, Grade IV
- Trial name
- ATTAC-II (NCT02465268)
- Testing
- pp65-shLAMP DC with GM-CSF, unpulsed PBMC and saline, Td
- Where
- 3 sites in United States
- Volunteers
- 175 people
- Sponsor
- University of Florida
Glioblastoma Multiforme, Glioblastoma
BrUOG 329 Onivyde & Metronomic Temozolomide in Recurrent Glioblastoma
New treatments are greatly needed for patients with recurrent glioblastoma. Metronomic temozolomide is a standard treatment option but has, at best, modest activity.
- Conditions
- Glioblastoma Multiforme, Glioblastoma, GBM
- Trial name
- 329 (NCT03119064)
- Testing
- Nanoliposomal Irinotecan, Temozolomide
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Brown University
Brain Tumor, Glioblastoma
Suberoylanilide Hydroxamic Acid (SAHA), Bevacizumab, Daily Temozolomide for Recurrent Malignant Gliomas
This is a Phase I/II open-label, single-arm study among recurrent malignant glioma patients. Patients will be treated with Vorinostat in combination with Bevacizumab (BV) (10 mg/kg) and Temozolomide (T) (50 mg/m2/day) BV is…
- Trial name
- NCT00939991
- Testing
- Vorinostst/Bevacizumab/Temozolomide
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Katy Peters
Brain Neoplasms, Central Nervous System Neoplasms
Phase I/II Bevacizumab Versus Bevacizumab Plus TPI 287 for Recurrent Glioblastoma
The goal of Part I of this clinical research study is to find the highest tolerable dose of TPI 287 that can be given with bevacizumab to patients with glioblastoma.
- Trial name
- NCT01582152
- Testing
- TPI287, Bevacizumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- M.D. Anderson Cancer Center
Brain and Central Nervous System Tumors
Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
RATIONALE: Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking some of the blood flow to the tumor.
- Trial name
- NCT00553150
- Testing
- everolimus, temozolomide, radiation
- Where
- 178 sites in United States
- Volunteers
- 122 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Recurrent Glioblastoma
Standard Chemotherapy vs. Chemotherapy Guided by Cancer Stem Cell Test in Recurrent Glioblastoma
The purpose of this clinical study is to confirm the utility of chemosensitivity tumor testing on cancer stem cells (ChemoID) as a predictor of clinical response in poor prognosis malignant brain tumors such as recurrent…
- Trial name
- CSCRGBM (NCT03632135)
- Testing
- ChemoID assay, Chemotherapy
- Where
- 13 sites in United States
- Volunteers
- 78 people
- Sponsor
- Cordgenics, LLC
Glioblastoma Multiforme, Gliosarcoma
Avastin/Temozolomide/Irinotecan for Unresectable/Multifocal Glioblastoma Multiforme
The primary objective of the study is to determine the efficacy of Avastin in combination with temozolomide and irinotecan in terms of response rate.
- Trial name
- NCT00979017
- Testing
- Avastin, Temozolomide, Irinotecan
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Katy Peters
Glioma
A Study of High-Dose Chemoradiation Using Biologically-Based Target Volume Definition in Patients With Glioblastoma
This is a study to determine the safety and effectiveness of high-dose radiation therapy (RT) with concurrent temozolomide in patients with newly diagnosed glioblastoma.
- Trial name
- NCT02805179
- Testing
- High Dose Radiation, Temozolomide
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- University of Michigan Rogel Cancer Center
Glioblastoma
A Study of Abemaciclib in Recurrent Glioblastoma
This research study is studying a targeted therapy as a possible treatment for recurrent glioblastoma (GBM). The following intervention will be used in this study: -Abemaciclib
- Trial name
- NCT02981940
- Testing
- Abemaciclib, Surgery
- Where
- 7 sites in United States
- Volunteers
- 45 people
- Sponsor
- Dana-Farber Cancer Institute
Glioblastoma Multiforme, Fibrillary Astrocytoma of Brain
Intraarterial Infusion Of Erbitux and Bevacizumab For Relapsed/Refractory Intracranial Glioma In Patients Under 22
Central nervous system (CNS) malignancies are the second most common malignancy and the most common solid tumor of childhood, including adolescence.
- Conditions
- Glioblastoma Multiforme, Fibrillary Astrocytoma of Brain, Glioma of Brainstem, Anaplastic Astrocytoma
- Trial name
- NCT01884740
- Testing
- SIACI of Erbitux and Bevacizumab
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Weill Medical College of Cornell University
Glioblastoma
Post Marketing Surveillance: Newly Diagnosed Glioblastoma Multiforme Treated With Radiotherapy/Temozolomide and Adjuvant Temozolomide (Study P04739)
The purpose of this surveillance is to collect more safety and efficacy data in "non-study" patients during concomitant and adjuvant temozolomide therapy.
- Trial name
- NCT00704808
- Testing
- Primary surgical treatment, Radiotherapy, Temozolomide
- Volunteers
- 180 people
- Sponsor
- Merck Sharp & Dohme LLC
Recurrent Glioblastoma
Ketogenic Diet for Recurrent Glioblastoma
To determine whether a mild ketogenic diet can influences quality of life and survival of patients with recurrent glioblastoma
- Trial name
- ERGO (NCT00575146)
- Testing
- TAVARLIN
- Where
- 2 sites in Germany
- Volunteers
- 20 people
- Sponsor
- University Hospital Tuebingen
Childhood Choroid Plexus Tumor, Childhood Ependymoblastoma
Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors
This phase I trial studies the side effects and best dose of palbociclib isethionate in treating younger patients with central nervous system tumors that have grown, come back, or not responded to treatment.
- Conditions
- Childhood Choroid Plexus Tumor, Childhood Ependymoblastoma, Childhood Grade III Meningioma, Childhood High-grade Cerebellar Astrocytoma
- Trial name
- NCT02255461
- Testing
- palbociclib isethionate, pharmacological study, laboratory biomarker analysis
- Where
- 11 sites in United States
- Volunteers
- 35 people
- Sponsor
- Pediatric Brain Tumor Consortium
Glioblastoma Multiforme
A Dose-finding Study of Birabresib (MK-8628) in Participants With Recurrent Glioblastoma Multiforme (MK-8628-002)
A study of single-agent birabresib (MK-8628) (formerly known as OTX015) in recurrent GBM after standard front-line therapy failure. The first phase of the study (dose escalation) will determine the maximum tolerated dose (MTD).
- Trial name
- NCT02296476
- Testing
- Birabresib
- Volunteers
- 12 people
- Sponsor
- Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Glioblastoma, Gliosarcoma
Imatinib Mesylate and Hydroxyurea in Treating Patients With Recurrent or Progressive Meningioma
RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as hydroxyurea, work in different ways to stop the growth of tumor cells…
- Trial name
- NCT00354913
- Testing
- hydroxyurea, imatinib mesylate
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Duke University
Glioblastoma Multiforme
Phase II Feasibility Study of Dendritic Cell Vaccination for Newly Diagnosed Glioblastoma Multiforme
Adult patients who have surgical resection of newly diagnosed glioblastoma multiforme will be treated with radiotherapy/chemotherapy followed by dendritic cell vaccine.
- Trial name
- NCT00323115
- Testing
- Autologous Dendritic Cell, Temozolomide, Radiotherapy
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Primary Stage IV Hepatobiliary, Esophageal
Improving Goals of Care Discussion in Advanced Cancer Patients
The goal of this study is to increase and improve Goals of Care discussions for advanced cancer patients by training medical oncologists to conduct these discussions.
- Conditions
- Primary Stage IV Hepatobiliary, Esophageal, Colorectal Cancer, Glioblastoma
- Trial name
- NCT02374255
- Testing
- GoC intervention
- Where
- 4 sites in United States
- Volunteers
- 265 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Glioblastoma
Bosutinib in Adult Patients With Recurrent Glioblastoma
For many brain tumors, one reason that chemotherapy drugs might not be effective is that the drug may not be able to get into the brain tumor and kill the cancer cells.
- Trial name
- NCT01331291
- Testing
- bosutinib
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- Massachusetts General Hospital
Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma
Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas
This phase I trial studies the side effects and the best dose of adavosertib when given together with local radiation therapy in treating children with newly diagnosed diffuse intrinsic pontine gliomas.
- Conditions
- Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant
- Trial name
- NCT01922076
- Testing
- Adavosertib, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 24 sites in United States, Canada
- Volunteers
- 46 people
- Sponsor
- National Cancer Institute (NCI)
Glioma
A Phase II Study of Pulse Reduced Dose Rate Radiation Therapy With Bevacizumab
To determine the efficacy of Pulse Reduced Dose Rate (PRDR) radiation when given in 27 fraction over 5.5 weeks with concurrent bevacizumab followed by adjuvant bevacizumab until time of progression in patients with recurrent high…
- Trial name
- NCT01743950
- Testing
- Bevacizumab, PRDR
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- University of Wisconsin, Madison